Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Cash (2016 - 2025)

Historic Change in Cash for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to -$98000.0.

  • Guided Therapeutics' Change in Cash fell 2098.77% to -$98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$107000.0, marking a year-over-year increase of 8007.45%. This contributed to the annual value of -$203000.0 for FY2024, which is 8821.14% up from last year.
  • Guided Therapeutics' Change in Cash amounted to -$98000.0 in Q3 2025, which was down 2098.77% from $70000.0 recorded in Q2 2025.
  • Over the past 5 years, Guided Therapeutics' Change in Cash peaked at $2.3 million during Q3 2022, and registered a low of -$627000.0 during Q3 2023.
  • Its 5-year average for Change in Cash is -$5000.0, with a median of -$146000.0 in 2024.
  • In the last 5 years, Guided Therapeutics' Change in Cash skyrocketed by 69081.36% in 2022 and then tumbled by 68048.78% in 2023.
  • Over the past 5 years, Guided Therapeutics' Change in Cash (Quarter) stood at $102000.0 in 2021, then plummeted by 476.47% to -$384000.0 in 2022, then soared by 63.54% to -$140000.0 in 2023, then surged by 238.57% to $194000.0 in 2024, then tumbled by 150.52% to -$98000.0 in 2025.
  • Its Change in Cash was -$98000.0 in Q3 2025, compared to $70000.0 in Q2 2025 and -$273000.0 in Q1 2025.